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Stromal Hedgehog signalling is downregulated in
colon cancer and its restoration restrains tumour
growth
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A role for Hedgehog (Hh) signalling in the development of colorectal cancer (CRC) has been
proposed. In CRC and other solid tumours, Hh ligands are upregulated; however, a speciﬁc Hh
antagonist provided no beneﬁt in a clinical trial. Here we use Hh reporter mice to show that
downstream Hh activity is unexpectedly diminished in a mouse model of colitis-associated
colon cancer, and that downstream Hh signalling is restricted to the stroma. Functionally,
stroma-speciﬁc Hh activation in mice markedly reduces the tumour load and blocks
progression of advanced neoplasms, partly via the modulation of BMP signalling and
restriction of the colonic stem cell signature. By contrast, attenuated Hh signalling accelerates
colonic tumourigenesis. In human CRC, downstream Hh activity is similarly reduced and
canonical Hh signalling remains predominantly paracrine. Our results suggest that diminished
downstream Hh signalling enhances CRC development, and that stromal Hh activation can
act as a colonic tumour suppressor.
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T
he Hedgehog (Hh) signalling pathway is one of the major
regulators of embryonic development. Later in life,
it can drive tumorigenesis: mutations that lead to cell-
autonomous Hh pathway activation cause nearly all basal
cell carcinomas, as well as subsets of medulloblastomas and
rhabdomyosarcomas1. By contrast, the majority of solid tumours,
including colorectal cancer (CRC), rarely carry mutations in Hh
genes2. Instead, in CRC, Hh ligand expression is upregulated and
conﬂicting data suggest either a paracrine role for Hh ligands in
shaping a tumour-supportive microenvironment3 or autocrine
pathway activation that promotes metastasis4.
Under homeostatic conditions, the main intestinal ligand,
Indian hedgehog (Ihh), is secreted by differentiated enterocytes,
whereas downstream signalling is activated exclusively in the
stroma5. In the ‘canonical’ Hh signalling cascade, binding of the
ligand to the inhibitory receptor Patched 1 (Ptch1) leads to
derepression of the activating receptor Smoothened (Smo),
thereby initiating a signalling cascade that culminates in the
stromal activation of the Glioma-associated oncogene (Gli)
proteins, Gli1, Gli2 and Gli3 (ref. 5). Gli1 expression is
considered the most reliable indicator of downstream pathway
activity, whereas Hh interacting protein (Hhip), Ptch1 and its
homologue Ptch2 are further common downstream targets6.
The SMO antagonist, vismodegib, has recently been approved
for the treatment of basal cell carcinomas7. Motivated by the
upregulation of Hh ligands in CRC, a clinical trial with
vismodegib added to ﬁrst-line therapy in metastatic CRC was
recently completed, but yielded a negative result8. A trial with
vismodegib in pancreatic cancer, in which Hh ligands are
similarly overexpressed, had an equally discouraging outcome9,
whereas a further pancreatic cancer study using another SMO
antagonist was halted due to an inferior outcome in the inhibitor-
treated group10. Collectively, these clinical data challenge the
paradigm of a tumour-promoting stroma shaped by Hh signalling
and contest a putative oncogenic role for cancer cell-autonomous
Hh activation in these tumour types.
Functionally, the stromal response to the Hh ligand is part of a
paracrine loop that controls differentiation of the intestinal
epithelium11. Diminished Hh signalling evokes an expansion of
the intestinal stem cell compartment and leads to impaired
enterocyte differentiation, as well as activation of Wnt signalling,
the central oncogenic driver pathway in CRC11–14.
Given this discrepancy between data suggesting a tumour-
promoting role for Hh in CRC on one hand and its pro-
differentiating role under homeostatic conditions, together with
negative results from clinical trials, on the other hand, we sought
to get a more precise picture of the role played by Hh in colorectal
tumourigenesis. Using Hh reporter mice, we provide evidence
that downstream Hh signalling activity is reduced in murine
colon tumours. Functionally, diminished Hh signalling promotes
colitis-associated colonic tumourigenesis in mice, whereas
stroma-speciﬁc Hh activation markedly curtails tumour develop-
ment. Similarly, human CRCs harbour diminished expression of
Hh downstream targets despite upregulated expression of the
ligand, Sonic Hh (SHH). Together, our data suggest that stromal
activation of Hh signalling can function as a suppressor of
colorectal carcinogenesis.
Results
Reduced stromal Hh signalling in murine colonic tumours. To
induce colonic tumours in mice, we employed a chemical model
based on injection of the mutagenic agent azoxymethane (AOM),
followed by repeated oral treatment with dextran sodium sulphate
(DSS) to induce epithelial damage and subsequent colitis
(Fig. 1a)15. Tumours in this model recapitulate central aspects of
human CRCs as they consistently exhibit mutations in the genes
for adenomatous polyposis coli (Apc) or catenin b1 (Ctnnb1)16,
and, less frequently, in Kras17. We consider this model
particularly well suited to our purposes, as it can be combined
readily with Cre-LoxP models to modify epithelial and
mesenchymal Hh signalling, and because tumours arise
speciﬁcally in the colon but not in the small intestine.
To assess downstream Hh signalling activity, we ﬁrst subjected
Gli1 reporter mice harbouring a b-galactosidase knock-in to Gli1
(Gli1lacZ/þ mice18), to AOM/DSS treatment, and then visualized
Gli1 expression with whole-mount X-gal staining. Although
non-malignant mucosa stained strongly, X-gal staining was weak
to absent in AOM/DSS-induced tumours (Fig. 1b). Histological
analysis revealed Gli1 expression exclusively in the stroma and
reduced X-gal staining in the tumours (Fig. 1c,d).
Real-time quantitative PCR conﬁrmed reduced Gli1 expression
in tumours from wild-type (wt) mice, with a congruent reduction
of the Hh targets, Hhip and Gli2 (Fig. 1e). Remarkably, expression
of the receptor, Ptch1, and its homologue, Ptch2, as well as the
main intestinal ligand, Ihh, was dissociated from attenuated
downstream Hh signalling (Fig. 1e), whereas all tumours
demonstrated increased Wnt activity, as expression of the Wnt
targets, Axin2 and Leucine-rich repeat-containing G-protein
coupled receptor 5 (Lgr5) was upregulated (Fig. 1e). RNA
in situ hybridization (ISH) conﬁrmed that downregulation of
stromal Gli1 can occur despite high Ihh expression in the adjacent
tumour cells (Fig. 1f).
Given that Hh downstream signalling in the intestine is
exclusively stromal5, the reduced expression of downstream Hh
targets could be the result of a reduction in the number of stromal
cells. To explore this possibility, we used immunoﬂuorescence
(IF) to stain for the intermediate ﬁlaments desmin, vimentin and
a-smooth muscle actin simultaneously. This marker combination
covers the majority of normal and cancer-associated non-
inﬂammatory stromal cells, for which no speciﬁc single marker
exists19. However, we saw no differences in the amount of stromal
cells between normal mucosa and adjacent tumours, indicating
that stromal cell loss is not the reason for diminished expression
of Hh downstream targets (Supplementary Fig. 1a–c).
Immunohistochemistry (IHC) of b-catenin in tumours from
Gli1lacZ/þ mice revealed its nuclear translocation in areas of low
stromal Gli1 expression (Fig. 1g), substantiating a model in which
the stromal downstream Hh signal is diminished in areas of high
epithelial Wnt activity. In line with this, we found that the
expression of p-Smads1/5—markers of epithelial differentiation
driven by bone morphogenetic protein (BMP) signalling that are
highly expressed in differentiated enterocytes20—correlated
spatially with stromal Gli1 (Fig. 1h).
Hence, colonic tumour development in the AOM/DSS model is
unexpectedly associated with a diminution in the stromal Hh
response. To explore Hh expression in a different colon cancer
model, we probed RNA-sequencing data from tumours in
which Apc activity is regulated by a doxycycline-dependent
short hairpin RNA (shRNA) (Gene Expression Omnibus (GEO)
data set GSE67186 and ref. 21). We found that these
non-inﬂammatory colon tumours recapitulated the expression
pattern of the AOM/DSS model, in that expression of the
downstream Hh targets, Gli1, Gli2, as well as Gli3, was reduced
signiﬁcantly and was dissociated from expression of the ligands,
Ihh (unchanged) and Shh (increased), as well as the receptor
Ptch1 (increased) (Supplementary Fig. 2a–c).
Increased tumour burden upon diminished Hh signalling. In
the murine colon, Ihh messenger RNA expression exceeds that of
Shh by several orders of magnitude (Supplementary Fig. 2a and
refs 22,23), and an Shh conditional knockout model revealed a
limited phenotype strictly conﬁned to the terminal ileum24.
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To assess whether reduced Hh signalling can promote malignant
transformation in the colon, we used a genetic model in which the
main intestinal ligand, Ihh, can be knocked out by Tamoxifen
(Tam) administration to VillinCreER;Ihhﬂox/ﬂox;R26-LSL-ZsGreen
mice (hereafter IhhDVil), simultaneously activating expression of a
conditional ﬂuorescent reporter. Although prolonged loss of Ihh
in intestinal epithelial cells leads to intestinal stem cell
accumulation, loss of differentiated cells and activation of the
Wnt pathway, it does not, by itself, result in adenoma
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AOM/DSS (Fig. 2a), we found a signiﬁcant increase in the
tumour burden compared with controls (Fig. 2b). The ZsGreen
reporter (indicating successful Cre-mediated recombination)
persisted throughout normal and tumourous epithelium,
demonstrating a permanent loss of Ihh and strongly suggesting
that tumour development is not dependent on Ihh expression
(Fig. 2c). Indeed, Ihh mRNA was barely detectable in IhhDVil
mice, Shh did not increase signiﬁcantly and stromal downstream
Hh targets were reduced (Fig. 2d and Supplementary Fig. 3a,b).
It is worth noting that IhhDViI mice lost more weight than
controls after DSS treatment and had a higher mortality, which
may imply that enhanced inﬂammatory activity contributes,













































































































































+/–50 mg kg–1 vismodegib
Figure 2 | Reduced Hh signalling increases tumour burden in the AOM/DSS model. (a) Schematic of Tam and AOM/DSS treatment of IhhDVil mice.
(b) Tumour numbers and tumour burden for IhhDVil mice (n¼ 13) and controls (n¼ 11 littermates that lacked either the VillinCreER allele or ﬂoxed Ihh alleles
or both): 5/13 IhhDVil mice and 11/11 controls reached the endpoint; P¼0.0321 (tumour numbers), P¼0.0215 (tumour burden; both t-tests).
(c) Representative confocal image of ZsGreen reporter ﬂuorescence in an IhhDVil mouse (upper left panel). Persistent reporter expression indicates
enduring loss of Ihh in the tumour. Haematoxylin and eosin (H&E) staining of consecutive section (upper right panel). Littermate wt controls are shown in
the lower panels. Dashed boxes show magniﬁed areas. Nuclear counterstain: TOPRO-3. Scale bars, 1mm/250mm. Representative image of n¼ 2 IhhDVil
mice with n¼ 8 tumours, in which all tumours expressed ZsGreen, whereas no zsGreen expression was detected in n¼ 3 control mice. (d) Real-time
quantitative PCR (RT-qPCR) for the indicated transcripts in IhhDVil mice (n¼ 5) and controls (n¼ 5); P¼0.003 (Ihh), P¼0.887 (Shh), P¼0.311 (Gli1),
P¼0.0142 (Ptch1; all t-tests, P-values after multiple test correction (fdr)). Bars represent mean and whiskers represent s.e.m. (e) Schematic of tumour
induction, vismodegib treatment and tumour quantiﬁcation with US; wt C57BL/6 mice received either 25mg kg 1 vismodegib or vehicle (DMSO) twice
daily, 6 days per week. (f) Tumour numbers and tumour burden for mice treated with vehicle (n¼ 16) or vismodegib (n¼ 15): 15/16 DMSO-treated and
10/15 vismodegib-treated mice reached the endpoint; P¼0.0014 (tumour numbers), P¼0.0036 (tumour burden; both t-tests). (g) Representative
histology of tumours from the indicated treatment groups (H&E); scale bars, 1mm/200mm. *Po0.05, **Po0.01 and ***Po0.001.
Figure 1 | Reduced stromal Hh activity in AOM/DSS-induced colon tumours. (a) Schematic of the AOM/DSS protocol. (b) Representative example of an
X-gal-stained tumour in a Gli1lacZ/þ mouse (from 420 tumours in 11 mice). Arrow indicates the tumour; r, rectum; m, normal mucosa. (c) Microscopic
appearance of an AOM/DSS-induced tumour in a Gli1lacZ/þ mouse after X-gal staining (representative of n¼ 11 tumours from n¼ 9 mice). Magniﬁcations
of normal mucosa: blue box and neoplastic tissue: red box; scale bars, 100/50mm. (d) Quantiﬁcation of X-gal-positive area in tumour and adjacent mucosa
(P¼0.0002; paired t-test). (e) Real-time quantitative PCR (RT-qPCR) for the indicated transcripts from tumours and matched normal mucosa, statistics
from paired t-tests based on the DCT values with multiple test correction (fdr, Benjamini and Hochberg): P¼0.003 (Gli1), P¼0.052 (Hhip), P¼0.0232
(Gli2), P¼0.199 (Ptch1), P¼0.314 (Ptch2), P¼0.771 (Ihh), Po0.0001 (Axin2) and P¼0.0016 (Lgr5); n¼ 11 tumours and adjacent mucosa from 11 wt mice;
at least 8 matched pairs analysed for each transcript. (f) RNA ISH for Ihh and Gli1 on consecutive sections of the same tumour/mucosa sample; scale bars,
50/10mm; dashed lines in magniﬁed sections denote epithelial compartment. (g) IHC of b-catenin in an X-gal-stained Gli1lacZ/þ tumour indicating mutual
exclusivity of epithelial Wnt activation and stromal Gli1; scale bars, 500/50mm. The graph compares the relative staining intensity of the DAB
chromophore at the tumour periphery and centre (n¼ 7 tumours, P¼0.006; box plots; whiskers represent minima and maxima). Arrowhead points to area
of positive X-gal staining. (h) IHC of p-Smads1/5 in a tumour from a Gli1lacZ/þ mouse. Scale bars, 100 mm. Quantiﬁcation of DAB intensity shows an
increase at the periphery, in parallel to stromal Gli1 (n¼ 6 tumours, P¼0.0002; unpaired t-tests in f and g); data presented as box-and-whisker plots,
whiskers represent minima and maxima. Arrowheads point to cells with positive X-gal staining indicating Gli1 expression. *Po0.05, **Po0.01 and
***Po0.001.
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In a subsequent experiment, we used vismodegib to antagonize
canonical Hh signalling at the level of the receptor Smo (Fig. 2e).
Twice daily administrations of vismodegib (25mg per kg body
weight) led to a signiﬁcant reduction in downstream Hh target
gene expression (Supplementary Fig. 3e). We treated C57BL/6 wt
mice with either vismodegib or vehicle and employed high-
frequency ultrasound (US) with intraluminal contrast to assess
polypoid colonic lesions at high resolution (Supplementary
Movies 1 and 2 and ref. 25). We found that inhibition of
canonical Hh signalling with vismodegib had an effect similar to
the Ihh knockout, in that it led to more frequent and larger
tumours (Fig. 2f,g). However, we observed no signiﬁcant
differences in terms of weight loss or mortality due to colitis
(Supplementary Fig. 3f,g).
Taken together, the data demonstrated that canonical
downstream Hh signalling is attenuated in murine colorectal
carcinogenesis, and that Hh inhibition can further accelerate
tumour development.
Stroma-speciﬁc activation of Hh signalling. To visualize Hh
target cells in a near-native setting, we crossed Gli1CreERT2
mice to Rosa26-LSL-tdTomato reporter mice, yielding inducible
Gli1CreERT2;Rosa26-LSL-tdTomato mice. Seven days after
administration of Tam, we found tdTomatoþ cells exclusively
residing in the stroma, including a mixed population of cells
expressing the cytoskeletal proteins desmin, vimentin and a-sma
(Fig. 3a).
Gli1 expression remained exclusively stromal after DSS-induced
epithelial damage, as indicated by analysis of both the Gli1lacZ/þ
and Gli1CreERT2;tdTomato reporter mice (Supplementary
Fig. 4a–d), indicating that downstream Hh signalling is not
activated ectopically in damaged epithelium.
In Gli1CreERT2 mice, Cre is knocked in to the endogenous
Gli1 locus18; thus, the loss of one functional Gli1 allele
alters downstream Hh signalling. To circumvent this problem
in further experiments aimed at activating Hh signalling
speciﬁcally in stromal cells, we used mice expressing Cre from a
transgenic collagen, type I, a2 (Col1a2) promoter26. Analysis
of Tam-induced Col1a2CreER;R26-LSL-tdTomato reporter
mice conﬁrmed recombination in an exclusively stromal cell
population (Fig. 3b) and collagen 1 protein expression overlapped
with tdTomato expression in Gli1CreERT2;Rosa26-LSL-tdTomato
mice (Fig. 3c). We found that Col1a2CreER targets a persistent
cell population as indicated by abundant tdTomatoþ ﬁbroblasts
100 days after recombination (Fig. 3d). As the Col1a2 transgene is
expressed in a wide range of organs26, we administered the active
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Figure 3 | Stroma-speciﬁc Cre-recombination in the murine colon. Initial tracing (7 days after Tam) and IF staining for the stromal proteins vimentin,
desmin, a-sma and the epithelial protein, integrin a-6, with TOPRO-3 as a nuclear counterstain: (a) Gli1CreERT2;R26-LSL-tdTomato mouse, representative
images from n¼ 3 mice. Comparison with the Gli1lacZ/þ model in the right panel; scale bars, 50mm. (b) Col1a2CreER;R26-LSL-tdTomato mouse with
representative images from n43 mice for each staining. Scale bars, 50mm. (c) 3D rendering of a 25mm-thick colon section from a Gli1CreERT2;R26-LSL-
tdTomato mouse 7 days after Tam treatment, stained for collagen-1 (Col1). Overlap of Gli1 and Col1 in yellow. Nuclear counterstain: 4,6-diamidino-2-
phenylindole (DAPI). Scale bar, 100mm. (d) Tomatoþ cells under the control of Col1a2CreER 100 days after Tam injection; scale bars, 500/50mm.
(e) Barium contrast enema illustrating colonic speciﬁcity of intraluminal 4OH-Tam instillations via the rectum (see also Supplementary Fig. 5).
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in subsequent experiments, where we employed Col1a2CreER-
expressing mice to activate Hh signalling speciﬁcally in the
stroma (Fig. 3e and Supplementary Fig. 5).
Hh activation antagonizes colonic tumour development. To
activate Hh signalling in Col1a2þ cells, we crossed Col1a2CreER
mice to Ptch1neo[D]Ex2[D] mice with LoxP-sites ﬂanking exon
2 of Ptch1 (ref. 27), creating Col1a2CreER;Ptch1ﬂox/þ mice
(hereafter Ptch1Col1(het)mice). In this model, Tam treatment leads
to the knockout of one Ptch1 allele speciﬁcally in Col1a2-
expressing stromal cells. Challenged with AOM/DSS (Fig. 4a),
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tumours than controls, revealing a protective effect of stromal Hh
activation on colorectal carcinogenesis (Fig. 4b,c). Following the
loss of one Ptch1 allele, Gli1 expression increased signiﬁcantly in
tumour tissue, whereas the effect in normal mucosa was less
pronounced, probably reﬂecting background Hh activity in
homeostasis (Fig. 4d). In line with this, we found no phenotypical
differences between wt littermates and Ptch1Col1(het) mice during
a 6-month follow-up after recombination (data not shown).
Moreover, we observed no differences between Ptch1Col1(het) mice
and control animals with respect to their sensitivity to DSS
treatment or mucosal immune cell composition at the endpoint
of the AOM/DSS protocol (Supplementary Fig. 6a,b). In tumours
from Ptch1Col1(het) mice, Gli1 transcripts were enriched in the
stromal compartment as expected (Supplementary Fig. 6c,d), yet
the amount of stroma did not differ signiﬁcantly between
tumours from control animals and those from Ptch1Col1(het) mice,
as assessed by IF (Supplementary Fig. 6e). Importantly, treatment
of Ptch1Col1(het) mice with vismodegib (Fig. 4e) overcame the
protective effect of Hh activation, indicating that it is largely
mediated in a Smo-dependent manner (Fig. 4f,g). Using
Ptch1Col1(het) mice, treated with vismodegib, and harbouring
an additional inducible tdTomato allele, we conﬁrmed that
Col1a2CreER-targeted cells remained exclusively stromal
throughout the AOM/DSS protocol (Fig. 4h), showing that Hh
activation remains conﬁned to the stroma in this model.
The loss of one Ptch1 allele had a marked effect on tumour
development, yet it did not detectably inﬂuence the course of the
DSS-induced colitis. Nevertheless, a role for Hh in modulating
the immune inﬁltrate in the colon cannot be excluded and
previous studies have suggested that stromal Hh signals can act as
modiﬁers of the intestinal immune response11,14. To investigate
the effect of Hh activation in a sporadic carcinoma model,
we induced tumours in Ptch1Col1(het) mice and controls with
consecutive AOM injections in the absence of DSS15 (Fig. 4i). In
accordance with AOM/DSS-treated mice, stromal Hh activation
attenuated tumour development in this model (Fig. 4j,k).
Collectively, our results indicated that Hh-driven stromal
signals can counteract the neoplastic transformation of overlying
epithelial cells.
Diminished BMP inhibitor expression upon Hh activation. To
investigate the functional consequences of stromal Hh activation
in greater depth, we performed gene expression analysis on
colonic tissue from Ptch1DCol1 mice, in which one pulse of Tam
induces homozygous inactivation of Ptch1 in the stromal com-
partment, resulting in activation of Hh signalling in normal
mucosa.
Gene expression data conﬁrmed the upregulation of Hh
targets (false discovery rate (fdr)¼ 0.001), dominated by Gli1,
Ptch1, Ptch2, and Hhip (Fig. 5a,b upper left panel and
Supplementary Tables 1 and 2). Gene set enrichment analysis
(GSEA) indicated a signiﬁcant enrichment of transcripts
associated with enterocyte differentiation (fdr¼ 0.086), such as
intestinal alkaline phosphatase (Alpi) or the brush border myosin
Ia gene (Myo1a) (Fig. 5b upper right panel and Supplementary
Table 3).
By contrast, Hh activation led to reduced expression of colonic
stem cell-associated genes (fdr¼ 0.0313), including Lgr5, Cdca7
and Cdk6, all of which are restricted to the stem cell compartment
at the crypt base (Fig. 5b lower left panel and Supplementary
Table 4)28. ISH conﬁrmed the reduced expression of Lgr5,
whereas Gli1 was increased as expected (Supplementary
Fig. 7a,b). These effects of augmented stromal Hh signalling
were paralleled by a marked reduction in secreted BMP inhibitors
such as Gremlin 1 (Grem1) and Noggin (Nog) (fdr¼ 0.092)
(Fig. 5b lower right panel and Supplementary Table 5).
Interestingly, Gdf10 (also known as Bmp3b), a member of the
BMP family exhibiting Hh-dependent expression, at least in the
brain29, was among the top 50 upregulated genes (Fig. 5a).
Stroma-speciﬁc Hh activation entailed further changes,
including alterations in known modiﬁers of intestinal tumour-
igenesis. For example, the mesenchymal factor, Foxl1, which was
upregulated in Ptch1DCol1 mice (Fig. 5a), is directly controlled by
Gli proteins30 and attenuates tumour development in a small
intestinal adenoma model31. As a further example, the gene
encoding plasma glutathione peroxidase (Gpx3), which has a
protective effect in the AOM/DSS model32, was similarly
upregulated (Fig. 5a).
To identify genes that show robust alterations in expression as
a result of Hh activation speciﬁcally in stromal cells, we analysed
two independent data sets: (i) human colonic ﬁbroblasts
(Fig. 5c,d) and (ii) murine intestinal mesenchymal cells
(Fig. 5e,f), treated with Hh ligands in vitro (based on the GEO
data sets GSE17840 and GSE29316 (refs 14,33)). In both cases,
activation of canonical Hh signalling was paralleled by signiﬁcant
upregulation of Foxl1/FOXL1 and signiﬁcant downregulation
of the BMP inhibitor Grem1/GREM1 (Fig. 5c–f). Other
BMP inhibitors such as Nog/NOG, Chrdl1/CHRDL1 and
Sostdc1/SOSTDC1 were signiﬁcantly downregulated in one of
the data sets, but not in both (Supplementary Table 6). Based on
these data, we revisited tumours from Ptch1Col1(het) mice, in
which Gli1 expression is increased (Fig. 4d), and analysed the
expression of selected BMP inhibitors using real-time quantitative
PCR. In line with the in vitro studies, we found that Grem1
Figure 4 | Stromal Hh activation attenuates colonic tumour development. (a) Experiment schematic; controls comprise littermates lacking either the
ﬂoxed Ptch1 allele or the Cre recombinase, or both. (b) Tumour numbers and cumulative tumour sizes in controls (n¼ 12 of which 10 reached the endpoint)
and Ptch1Col1(het) mice (n¼ 12 of which 10 reached the endpoint). Po0.0001 (for both tumour number and burden, t-tests). (c) Histology (haematoxylin
and eosin (H&E)) of representative tumours from each group presented in b); scale bars, 1mm/200mm. (d) Gli1 mRNA expression in normal mucosa
(n¼8 controls and n¼6 Ptch1Col1(het) mice; P¼0.235) and tumours (n¼ 10 tumours from controls and n¼ 9 tumours from Ptch1Col1(het) mice; P¼0.002);
t-test statistics on DCT values. Bars represent means and whiskers represent s.e.m. (e) Schematic of vismodegib administration (25mg kg 1 body weight
twice daily, 6 days per week), Tam administration and tumour induction. (f) Tumour numbers and cumulative sizes in controls (littermates as deﬁned in b
that received Tam and twice daily injections of dimethyl sulfoxide (DMSO); n¼ 17 of which 13 reached the endpoint), Ptch1Col1(het) mice (n¼ 13 of which all
reached the endpoint) and Ptch1Col1(het) mice (treated with vismodegib twice daily, 6 days per week, n¼ 19 of which 12 reached the endpoint). P-values from
one-way analysis of variance with Tukey’s multiple comparison test are indicated. (g) Representative histology (H&E staining) of a Ptch1Col1(het) mouse
treated with vismodegib. (h) Confocal image of a Ptch1Col1(het) mouse with an inducible R26-LSL-tdTomato reporter, treated with vismodegib. TdTomatoþ
cells are exclusively stromal in tumour (middle panel representing magniﬁcation of boxed area in the left panel) and normal tissue (right panel
magniﬁcation); stromal marker: a-smooth muscle actin (a-sma) (blue); epithelial marker: Ita6 (green); nuclear stain: 4,6-diamidino-2-phenylindole (DAPI).
Scale bars, 1mm/100mm. Representative of n¼4 tumours in n¼ 2 mice. (i) Schematic of AOM injections and Tam administration (repeated as Col1a2þ
progeny were known to persist at least for up to 100 days; Fig. 3d). (j) Tumour numbers and volumes for Ptch1Col1(het) mice and controls (n¼6 littermates
as deﬁned in b, of which ﬁve (controls) and four (AOM) reached the endpoint; P¼0.143 and P¼0.045, respectively, t-tests). (k) Representative histology
of the AOM-induced tumours for the indicated genotypes. Scale bars, 1mm/200mm. Whiskers represent s.e.m.; *Po0.05, **Po0.01 and ***Po0.001.
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Figure 5 | Transcriptional changes upon Hh activation. (a) Heatmap of the 50 highest ranked genes (using the GSEA algorithm58) in the murine
colon upon knockout of stromal Ptch1 in Ptch1DCol1 mice (n¼4) versus controls lacking Cre recombinase (n¼4) 7 days after a single dose of 5mg Tam i.p.
(b) GSEA indicates activation of canonical Hh signalling (left upper panel); enrichment of genes associated with enterocyte differentiation (right upper panel, gene
ontology (GO) term, GO:0005903) and downregulation of colonic stem cell-associated genes (left lower panel) in parallel with loss of secreted BMP inhibitors
(right lower panel). Normalized enrichment score (NES), P-value and fdr are indicated in each panel; gene lists are presented in the Supplementary Material.
(c) Gene expression of indicated transcripts in the human colon ﬁbroblast cell line, CCd-18Co, treated with 1mgml 1 SHH or vehicle for 72h (data derived from
GEO29316 (ref. 33)). (d) Illustration of signiﬁcant changes in gene expression (fdr adjusted); note highly signiﬁcant downregulation of GREM1 and NOG, and
upregulation of FOXL1. (e) Gene expression in cultured intestinal mesenchyme from E18.5 mouse embryos treated with Ihh or Shh amino-terminal polypeptide
(2.5mgml 1) or vehicle for 24h (data derived from GEO17840); scale as in c. (f) Illustration of signiﬁcant changes in gene expression (fdr adjusted); Grem1 was
downregulated by both Shh and Ihh treatment; upregulation of Gdf10, Gpx3 and Foxl1 was signiﬁcant in Shh-treated mesenchyme. Scale as in d. (g) mRNA
expression of the indicated transcripts in tumours of Ptch1Col1(het) mice (n45) and tumours from control mice (lacking Cre recombinase, ﬂoxed Ptch1 alleles or both;
n48); P-values from t-tests with fdr correction indicated, P¼0.001 (Grem1), P¼0.558 (Nog), P¼0.603 (Chrd), P¼0.206 (Bambi) and **Po0.01.
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Figure 6 | Growth arrest of established murine tumours upon stromal Hh activation. (a) Protocol schematic. (b) Example of a 3D mUS reconstruction;
tumour volume (arrow) is highlighted in red, other hypoechoic (black) structure is the urinary bladder (ub); lu: colonic lumen, ﬁlled with US gel; vaw: ventral
abdominal wall. (c) Tomatoþ cells in an AOM/DSS-induced tumour from a Col1a2CreER;R26-LSL-tdTomato mouse 3 days after Tam administration;
b-catenin (green) marks tumour cells; nuclear stain: 4,6-diamidino-2-phenylindole (DAPI); scale bar, 100mm. (d) Tumour size as measured by mUS after
Tam instillation (week 0). A total of n¼ 5 Ptch1DCol1 mice with n¼ 11 tumours and n¼ 7 controls (littermates lacking Cre recombinase, ﬂoxed Ptch1 alleles or
both) with n¼ 12 tumours are included; 1 to 5 tumours per mouse were analysed. The adjusted P-values (fdr) from t-tests are indicated: P¼0.406
(week 0), P¼0.022 (week 1), P¼0.029 (week 2), P¼0.026 (week 3), P¼0.026 (week 4) and P¼0.078 (week 5). Box-and-whisker plots: whiskers
represent minima and maxima. In the control group, mice had to be killed because of bleeding per anus, leaving 2 tumours for US analysis in week 5 and
none in week 6. (e) Quantiﬁcation of cleaved caspase-3 positivity per high-power ﬁeld (original magniﬁcation 400): controls (n¼9 tumours),
Ptch1DCol1mice (n¼ 5 tumours), P¼0.0034 (t-test). Middle and right panels show representative IHC images for similar-sized tumours 3 weeks after Tam
treatment for the indicated genotypes. Scale bars, 20mm. (f) Proliferative index as a percentage of Ki67þ nuclei for n¼ 7 controls and n¼4 tumours from
Ptch1DCol1 mice, P¼0.0467 (t-test) and representative images (middle and right panels). Scale bars, 50/20mm. (g) ISH semi-quantiﬁcation of Grem1 in
control mice (n¼ 5 tumours) and Ptch1DCol1mice (n¼ 7 tumours). Stacked bars represent the frequency of intensity grading; P¼0.0076 (Mann–Whitney
test), middle and right panels show representative images for the two groups; scale bars, 200/100mm. (h) Quantiﬁcation of p-Smad1/5 IHC in control mice
(n¼8 tumours) and Ptch1DCol1 mice (n¼9 tumours); P¼0.0028 (t-test), middle and right panels show representative images for the two groups; scale
bars, 50mm; (e–h) boxed areas show magniﬁed regions. *Po0.05, **Po0.01 and ***Po0.001.
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expression is downregulated in tumours from Ptch1Col1(het) mice
compared with controls (Fig. 5g).
Together, the data indicated that stromal Hh activation leads to
complex transcriptional changes with a prominent, but not
exclusive, role for the modulation of BMP signalling. These
changes result in restriction of the colonic stem cell state
signature and induction of epithelial differentiation markers.
Hh activation blocks the growth of established tumours.
AOM/DSS treatment of Ptch1DCol1 mice led to severe morbidity
and mortality, precluding their use for the study of tumour
initiation (Supplementary Fig. 7c,d,e). Without AOM/DSS
treatment, Ptch1DCol1 mice had to be killed several weeks after
Tam treatment, as they developed large, cystic stromal tumours
predominantly at the ileoceacal junction, which occasionally
ruptured or led to gross abdominal distension (Supplementary
Fig. 7f,g). Similar tumours have been described in a related model,
in which Ptch1 was speciﬁcally inactivated in a more restricted
stromal compartment34.
Nevertheless, we were able to induce tumours with AOM/DSS
in Ptch1DCol1mice that had not received Tam previously and we
used this model to activate Hh signalling in established tumours.
It has recently been shown that high levels of Wnt signalling
are necessary for tumour maintenance, and that restoration
to homeostatic Wnt levels causes tumour regression21. This
prompted us to ask whether activated stromal Hh signalling
might restrain tumour growth in a similar manner. Once
AOM/DSS-induced lesions of similar sizes were detected, we
used three-dimensional (3D) mUS to monitor tumour volumes
over time in Ptch1DCol1 mice and control mice after Tam
administration (Fig. 6a,b). Using Col1a2CreER;R26-LSL-tdTomato
mice, we conﬁrmed that tdTomatoþ cells were directly adjacent
to the tumour cells (Fig. 6c).
One week after Tam treatment, delayed growth was evident in
tumours from Ptch1DCol1 mice compared with littermate controls
(Fig. 6d). Over the course of several weeks, tumours with
Hh-activated stroma frequently entered permanent macroscopic
growth arrest or, in the case of smaller lesions, showed regression,
whereas tumours in control animals progressed (Fig. 6d
and Supplementary Movies 1 and 2). IHC analysis of cleaved
caspase-3 (Fig. 6e) and Ki67 (Fig. 6f) indicated increased tumour
cell apoptosis and diminished proliferative activity, respectively,
following stromal Hh activation.
To assess whether Grem1 is reduced as a consequence of
stromal Hh activation in the tumours, we used RNA ISH and
semi-quantitatively evaluated the staining intensity35. Although
Grem1 was strongly expressed in the tumour stroma of control
mice, expression was signiﬁcantly reduced in Ptch1DCol1 mice
(Fig. 6g). In addition, tumour-epithelial p-Smad1/5 staining was
consistently more abundant in tumours from Ptch1DCol1 mice,
indicating increased epithelial BMP downstream activity as a
result of the augmented stromal Hh signal (Fig. 6h).
Diminished downstream Hh response in human colon cancer.
Based on the unexpected expression patterns of Hh pathway
members in murine tumours, we decided to re-assess Hh
expression in human CRC in more detail, including the pathways’
downstream targets. To this end, we ﬁrst analysed microarray
gene expression data from The Cancer Genome Atlas (TCGA),
representing 155 colon cancer patients2. Although SHH was
upregulated in carcinomas as previously reported3, IHH was
moderately downregulated (Fig. 7a). As in the mouse model, the
downstream targets, GLI1 and HHIP, were downregulated
(Fig. 7b) and, strikingly, no correlation between GLI1 and Hh
ligand expression was observed (Fig. 7c). In addition, we found
that the BMP targets, ID1 and ID2, were signiﬁcantly
downregulated in the carcinomas, whereas GREM1 and NOG
expression increased, albeit not signiﬁcantly in the case of
GREM1 (Fig. 7d). Moreover, expression of the BMP ligands,
GDF10/BMP3b and BMP5, was reduced signiﬁcantly (Fig. 7d).
In some colon cancer cell lines with mutations in KRAS
or BRAF, cancer cell-autonomous GLI1 activation has been
described36. However, we found no correlation between the
presence of mutated KRAS or BRAF and GLI1 mRNA levels
(Supplementary Fig. 8a). Instead, there was a weak but signiﬁcant
correlation between mutations in the APC gene and low GLI1
levels (Supplementary Fig. 8a).
GLI1 mRNA levels correlated well with stromal gene expres-
sion signatures in the TCGA data set (Supplementary Fig. 8b),
indicating that activation of downstream Hh signalling is largely
conﬁned to the stromal compartment. To conﬁrm this further,
we probed gene expression data from CRC patient-derived
xenografts, in which murine stromal cells replace the human
stroma after transplantation (based on GEO GSE56710 and
GSE35144 data sets)37. In the xenografts, expression of the
ligands, SHH and IHH, was exclusively epithelial, whereas
downstream signalling was largely restricted to the stroma, as
transcripts of GLI1 (475%) and GLI2 (95%), as well as HHIP
(100%) were predominantly or exclusively murine (Fig. 7e).
To assess gene expression in the different cellular compart-
ments in a more quantitative manner, we analysed Hh and BMP
pathway components in CRCs sorted for epithelial cells (CD45 ,
Epcamþ ), leukocytes (CD45þ , Epcam ) and stromal cells
(CD45 , Epcam ; based on the GEO39395 data set)38. We
found a similar pattern to that in the xenografts, such that
downstream Hh targets were enriched in the stroma to a highly
signiﬁcant degree, whereas ligand expression was epithelial
(Fig. 7f,g). GREM1 and the BMP ligand BMP5 were enriched
signiﬁcantly in the stromal fraction, in keeping with the results
from the mouse model, whereas tumour cells expressed BMP4 in
several cases. Of note, the Hh co-receptor CDON and PTCH1
were expressed in the tumour cells at a level similar to that seen in
the stroma, although this did not lead to increased expression of
Hh downstream targets in the epithelial compartment (Fig. 7f).
In summary, the results obtained from different CRC cohorts
demonstrated that human colon cancer exhibits a marked
decrease in downstream Hh target gene expression, which is
predominantly, if not exclusively, of a stromal nature.
Discussion
Under homeostatic conditions, the mode of intestinal Hh
signalling is exclusively paracrine, from the ligand-secreting
epithelium to the receptive underlying stroma11,39. However,
a role for cell-autonomous downstream Hh activity in colon
cancer cells has been suggested, in particular at later tumour
stages, in which Hh activation drives metastasis4,40.
In the current study, our analyses of stromal and epithelial
gene expression strongly suggest that there is little, if any,
cell-autonomous Hh downstream activity in colon cancer cells
(Fig. 7e,f). Together with the marked overall downregulation of
GLI1 and HHIP (Fig. 7b), these results provide consistent
evidence that stromal downstream Hh activity is diminished in
colon cancer. However, as some CRC cell lines are dependent on
GLI1 (refs 36,40), it is possible that downstream Hh signalling
might play a role in a tumour cell subpopulation. On the other
hand, most CRC cell lines do not express a complete set of Hh
downstream targets41. Aside from a role for canonical Hh
signalling, it has previously been suggested that Hh ligands can
prevent colon cancer cells from entering apoptosis by binding to
the dependence receptor, CDON, in an autocrine manner
(independent of the role of CDON as a Hh co-receptor)42.
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As we ﬁnd that CDON is expressed in the tumour cell
compartment (Fig. 7f), this leaves a possible tumour-promoting
role for a non-canonical SHH/CDON/PTCH1 axis, acting
independently of downstream Hh signalling (Fig. 7h).
In contrast to carcinomas, human colonic adenomas from
patients with familial adenomatous polyposis as well as small
intestinal adenomas from Apclox15 mice exhibit increased levels of
IHH/Ihh and GLI1/Gli1 (ref. 12). In Apclox15 mice the presence
of Ihh is required for adenoma development12, whereas in
the AOM/DSS model Ihh loss fuels tumourigenesis (Fig. 2a).
Importantly, treatment of later stage small intestinal murine
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tumour growth in the Apcmin model12. Almost all functional data
on intestinal Hh signalling from in vivomodels have thus far been
acquired in the small intestine11–14,43. However, the tissue
architecture and cellular composition of the small intestine
differ considerably from those of the colon, in which the vast
majority of human intestinal cancers arise. It is therefore
noteworthy that colonic tumours in mice, whether they are
induced chemically with AOM/DSS (Fig. 1), or genetically, as in
the ShApc model21 (Supplementary Fig. 2), recapitulate the Hh
expression pattern seen in human CRCs12. Hence, tissue-speciﬁc
properties of the small intestine and colon may explain the
different requirements in the two locations with regard to
dependence on Hh signalling.
Across various colon cancer mouse models and in human
CRC, downstream Hh activity can be lost despite increased ligand
expression (Figs 1 and 7, and Supplementary Fig. 2). This might
be the result of alterations in stromal gene expression
programmes that render stromal cells indifferent to the epithelial
ligand44. An alternative explanation has recently been proposed
by Shyer et al.45, who found that during development Hh ligands
are concentrated at the villus tips merely as a result of the physical
folding of the epithelium. This leads to Hh activation in the
stroma and differentiation of the epithelium at the villus tips45.
It is tempting to speculate that, as a result of perturbations in the
tissue architecture during tumourigenesis, ligand concentrations
are insufﬁcient to activate downstream Hh signalling in the
tumour stroma. Interestingly, in the Apc-shRNA model, the
expression of Gli1, Gli2, and Hhip is consistently reduced
further in tumours carrying an additional mutation in Kras
(Supplementary Fig. 2c), which show higher levels of dysplasia
than tumours in Apc-shRNA animals, as well as invasive
behaviour, supporting a model in which disrupted tissue
architecture interferes with ligand availability and induction
of the stromal Hh response21. Moreover, in our hands,
AOM/DSS-induced tumours occasionally displayed signs of
invasion through the muscularis mucosae (Supplementary Fig. 9
and refs 16,46).
Although the AOM/DSS model recapitulates the Hh expres-
sion pattern of human CRC as well as parts of the mutagenic
landscape of sporadic human colon cancers16, tumour
development is accelerated by colitis, which is not a self-evident
feature of most human carcinomas. Nevertheless, sporadic
colorectal carcinogenesis is characterized by, and is dependent
on, a complex inﬂammatory cell inﬁltrate and immuno
compromised mice are protected from both inﬂammatory-
associated and sporadic colon tumours47,48. On a clinical note,
our data indicate that caution is warranted particularly when
using Hh antagonists in patients with inﬂammatory bowel
disease, who are at an increased risk of developing CRC49.
However, together with data from pancreatic and bladder cancer,
in which Hh antagonism similarly accelerates carcinogenesis50,51,
our results point to the possibility that treatment with Hh
antagonists could increase the risk for several solid malignancies,
including CRC.
Functionally, the data suggest a dominant, but not exclusive
role for BMP modulation as a mediator of stromal–epithelial
crosstalk. BMP signalling is active in adenomas, but is down-
regulated in CRCs52 (Fig. 7d) and thus mirrors the expression
pattern of downstream Hh effectors. In sporadic CRC, high
GREM1 expression is associated with treatment resistance and
inferior survival53. Moreover, ectopic epithelial expression of
GREM1 causes hereditary mixed polyposis syndrome, which is
characterized by the appearance of multiple colonic polyps that
frequently progress to carcinomas54. This can be modelled in
mice, where ectopic Grem1 expression leads to the reacquisition
of stem cell properties in differentiated cells53, which are
consequently able to initiate intestinal neoplasia. We show that,
as a consequence of Hh activation, attenuated BMP inhibitor
expression is conversely associated with diminution of the
intestinal stem cell signature (Fig. 5a,b). Thus, it seems plausible
that loss of stromal BMP inhibitors due to the activation of stromal
Hh signalling (Fig. 5b) may have the potential to restrain colonic
tumour initiation and progression (Fig. 7h).
The importance of paracrine Hh signalling in tumour–stroma
cross-talk has been recognized for more than a decade—yet
accumulating data now indicate that Hh-driven signals might
represent exploitable targets that are not limited to colon cancer
therapy, but extend to other cancer types.
Methods
Mice. C57BL/6 mice (referred to as wt) were obtained from Scanbur, Sweden, and
used at48 weeks of age. All mice were on a C57BL/6 background. Gli1lacZ/þ and
GliCreERT2 mice were a kind gift from Fritz Aberger, whereas R26-LSL-tdTomato
(B6.Cg-Gt[ROSA]26Sortm14[CAG-tdTomato]Hze/J) and Col1a2CreER
(B6.Cg-Tg[Col1a2-cre/ERT]7Cpd/J) mice were obtained from the Jackson
Laboratory (Bar Harbor, USA). Ptch1ﬂ/þ mice have been described previously27.
For IhhDVil mice, VillinCreERT2 mice were crossed with Ihhﬂox/ﬂox mice and
Rosa26-ZSGreen mice, to generate VillinCreERT2-ZsGreen-Ihhﬂox/ﬂox animals.
Mice receiving DSS were assessed daily in a cumulative score until recovery
(weight, movement and body posture, piloerection, skin condition, food
consumption, excretions and breathing). Littermates were used as controls and
experimental groups were housed in one cage wherever possible. In the case of Cre/
Lox-p models, the control animals lacked either the Cre or ﬂoxed alleles or both.
Chemical models of CRC. AOM (Sigma-Aldrich, A5486) at 12.5mg kg 1
bodyweight was administered intraperitoneally (i.p.) on day 0 and DSS (DB001;
Figure 7 | Diminished Hh signalling in human colonic adenocarcinomas. (a) TCGA analysis (box plots) of Hh ligand expression and (b) expression of Hh
downstream targets in 155 human colon carcinomas; P-values (Wilcoxon rank-sum test) are indicated in the panels. (c) Correlation between GLI1
expression and expression of HHIP, PTCH1, IHH and SHH; correlation coefﬁcients and P-values are given in the panels. (d) Expression of the BMP targets ID1
and ID2, the BMP inhibitors GREM1 and NOG, and the BMP ligands BMP5 and GDF10. P-values are indicated in the panels. (e) Analysis of Hh pathway
expression in patient-derived xenografts, based on bi-species RNA-sequencing data37. Hh ligands are expressed exclusively by human tumour cells,
whereas transcripts of downstream targets are mostly of murine origin (that is, stromal). Expression of SMO and PTCH1, as well as its homologue PTCH2, is
seen in both compartments (middle panel). (f) Illustration of gene expression in human CRC (n¼8) sorted for tumour/epithelial cells (Epcamþ , CD45 ),
leukocytes (Epcam , CD45þ ) and ﬁbroblasts (double negative). Each column represents expression data from an individual patient for each compartment
(based on GEO data set GSE39395). (g) Differential expression of the indicated transcripts in comparison with stromal expression. Red/blue cells indicate
signiﬁcant up-/downregulation in the stroma; fdro0.05. (h) Model of Hh signalling in CRC: ﬁbroblasts (grey) express the Hh receptors, PTCH1 and SMO,
and respond to tumour cell-derived ligand by activation of canonical Hh signalling. Reduced stromal Hh aticvity is associated with paracrine inhibition of
BMP signalling, partly mediated via derepression of GREM1. Tumour cells (orange) are largely incapable of canonical Hh signalling. However, the Hh
co-receptor CDON and possibly PTCH1 itself may function as dependence receptors for the ligands, IHH and SHH, and inhibit tumour cell apoptosis.
Upon activation of canonical Hh signalling in the stroma, for example, by knockout of PTCH1 (‘X’, lower panel), expression of BMP inhibitors is repressed,
whereas expression of BMP ligands such as GDF10 is upregulated, cumulatively leading to enhanced BMP signalling in the tumour cells. Other stromal
factors, such as FOXL1 and GPX3, may contribute independently of BMP signalling to the protective effect of active stromal Hh signalling. *Po0.05,
**Po0.01, ***Po0.001 and ****Po0.0001.
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Tdb Consultancy, Sweden) was initiated at a concentration of 2% on day 5 and was
administered for 5 days15. DSS cycles were repeated twice with 14 days of normal
drinking water in between. All DSS preparations were renewed after 2 days. For the
sporadic model, AOM was administered i.p. once a week at 12.5mg kg 1 body
weight for 10 consecutive weeks.
For IhhDVil mice speciﬁcally, 10-week-old animals were injected i.p. with 1mg
Tam (T5648; Sigma-Aldrich) for 5 consecutive days. Two weeks after Tam
initiation, mice were injected with AOM (10mg kg 1) and received drinking water
supplemented with 1.75% DSS for 4 days, which was then changed to untreated
drinking water. During weeks 5 and 8, the mice received 1.25% DSS for 4 and
3 days, respectively. The DSS concentration and treatment duration were adjusted
due to augmented weight loss. After 12 weeks, the mice were killed.
Vismodegib and Tam treatment. Vismodegib (V-4050, LC Laboratories) was
administered i.p.55,56 in dimethyl sulfoxide twice daily at 25mg kg 1 body weight
for 6 days per week.
For intracolonic administration, 4OH-Tam (H6278; Sigma-Aldrich) was
dissolved in 99.5% ethanol, vortexed, further diluted in corn oil (S5007, Sigma-Aldrich)
to reach the working concentration and sonicated for 30min at 37 C in a water
bath. The solution was kept at 37 C in darkness until it was instilled intraluminally
at 1mg 25 g 1 bodyweight. Instillation was performed with US guidance under
isoﬂurane anaesthesia (described below). For visualization of the instilled substance
with microcomputed tomography (mCT) imaging, 0.1mgml 1 barium sulphate
(Barium Sulphate (#11381499) 97%, Alfa Aesar) was added to the Tam/oil
suspension. The mCT was performed under isoﬂurane anaesthesia
(see below) using a Quantum FX mCT imaging system (Caliper Life Sciences,
Perkin Elmer, Inc.) a few minutes after administration of the Tam/oil/barium
mixture.
For systemic labelling experiments in Col1a2CreER;R26-LSL-tdTomato and
Gli1CreERT2;R26-LSL-tdTomato mice, 5mg of Tam was dissolved in corn oil using
sonication at 37 C at 20mgml 1 and injected once i.p.
Ultrasound. The Vevo 2100 system (Visualsonics, Canada) was used for
high-frequency US57. Mice were anaesthetized with 1–2% v/v isoﬂurane (Baxter,
KDG9621). Hair over the abdomen was removed using a depilatory cream. The
mice were scanned in a supine position on a heating plate (40 C) with constant
cardiovascular monitoring and protective eye ointment. Scans were performed at
40MHz (probe MS550D; axial resolution 40 mm) using a 3D-motor for z axis
resolution57. For administration of intraluminal contrast during colonic imaging, a
plastic gavage tube was advanced carefully via the anus and small amounts of US
gel were injected to inﬂate the colonic lumen gently under US surveillance. The
largest tumour cross-sectional area was determined visually. For 3D scanning, the z
resolution was set to 76mm and the whole tumour length was scanned. Tumour
outlines were drawn manually for each slice and 3D reconstruction was performed
using Visualsonics Vevo software (v1-5.0).
Immunoﬂuorescence. For IF, the colon was removed, faeces were gently washed
out with cold PBS and the tissue was immediately frozen on dry ice in Tissue-Tek
O.C.T. compound and stored at  80 C. Sections were cut using a cryotome at
20–100 mm and incubated for 30min in PBS with 0.5% Triton X-100 (Sigma-
Aldrich; T8787) and 0.1% TOPRO-3 (Invitrogen; T3605). Slides were mounted
between two coverslips (Menzel, Nr. 1.5 (0.16–0.19mm)) and scanned using a
Zeiss LSM710 confocal microscope in single-photon mode. For antibody staining,
20–100 mm sections were cut in a cryotome and incubated overnight in antibody
diluted in PBS plus 0.5% Triton-X-100, 0.5% BSA and 0.5% dimethyl sulfoxide at
4 C. A species-appropriate secondary antibody (1:250 dilution) was chosen from
Alexa Fluor dyes (Invitrogen) using an appropriate wavelength depending on the
primary antibody and the presence of endogenous ﬂuorophores. The antibodies
and dilutions were as follows: anti-vimentin (Santa Cruz, sc7557, 1:500);
anti-desmin (Abcam, ab8592, 1:500); anti-a-sma (Abcam, ab5694, 1:500);
anti-collagen1 (Abcam, ab34710, 1:200); anti-b-catenin (Cell Signalling, #9582,
1:100); anti-Ita6 (CD49f, BD Pharmigen, # 555734, 1:100).
IHC and X-gal staining. For IHC, the colon was incised longitudinally and ﬁxed in
4% paraformaldehyde (PFA) in PBS overnight at 4 C before routine processing
and parafﬁn embedding. Next, 4 mm sections were baked at 60 C for 1 h and
rehydrated.
The sections were subjected either to a heat-induced epitope retrieval step or to
proteinase-induced epitope retrieval, depending on the primary antibody used.
Heat-induced epitope retrieval was performed in citrate buffer (pH 6) or DIVA
reagent (Biocare Medical, DV2004) using a pressure cooker. Protein-induced
epitope retrieval was performed in a 37 C water bath using 0.05% protease
(Sigma). Sections were incubated with antibodies against B220 (eBioscience;
clone RA3-6B2; 1:200), CD3 (Dako; #N1580; 1:20), F4/80 (Invitrogen; clone BM8;
1:100), MPO (Dako #A0398; 1:500), b-catenin (Cell Signalling; #9582; 1:100),
phospho-smad1/5 (Ser463/465; Cell Signalling; 9516S; 1:50), cleaved caspase-3
(Asp175; Cell Signalling; 9661S; 1:200) or Ki67 (Novocastra; NCL-Ki67p; 1:200) for
1 h at room temperature (RT). After rinsing, the sections were incubated with a
biotinylated secondary antibody: donkey anti-rabbit, rabbit anti-rat antibody
(Dianova) or rabbit anti-goat (Vector, BA-5000), followed by incubation with
alkaline phosphatase-labelled streptavidin (Dako; CD3, B220, F4/80, MPO,
b-catenin) for 30min at RT or streptavidin peroxidase (Invitrogen; for all others).
Alkaline phosphatase was revealed with Fast Red (Dako; AR17911-2) and
peroxidase was revealed with DAB (Invitrogen; DAB plus reagent kit; #002020).
Sections were counterstained with haematoxylin or eosin (for X-gal stained tissue)
and slides were mounted with water-based mounting medium (Polyscience;
#18606). Negative controls omitted the primary antibodies. Triple-IF was
performed with antibodies against desmin (AF3844, R&D, 1:200) and vimentin
(#5741, Cell Signalling, 1:100), followed by secondary antibodies as described above
together with a Cy3-coupled anti-sma antibody (C6198, Sigma Aldrich, 1:200).
X-gal staining was performed as previously described with slight
modiﬁcations27. Brieﬂy, colon tissue was ﬁxed in 2% PFA/PBS with 0.2% v/v
glutaraldehyde for 30min at RT. Tissues were washed once for 15min in 2mM
MgCl in PBS plus 0.01 % Nonidet P-40 (BDH Laboratory Supplies; #56009).
Tissues were incubated for 15 h at 37 C in X-gal substrate solution (stock solution:
100ml of washing buffer, 1ml of 5mM potassium ferricyanide, 1ml of 5mM
potassium ferrocyanide and 2.5ml of 40mgml 1 X-gal (Sigma, B9285) in
N,N-dimethylformamide). Specimens were washed once in PBS, ﬁxed in 4%
PFA/PBS for 4 h at RT and parafﬁn embedded.
Microphotographs were taken using a Leica DMLB microscope with a Leica
DC300F camera or with a Panoramic MIDI scanner (3DHISTECH), imported with
PanoramicViewer software (v.1.15.4). Adobe Photoshop (CS5, v12.1) was used to
adjust brightness and contrast. Changes were always applied to the whole image.
The colour deconvolution plug-in for ImageJ was used to quantify DAB and
X-gal intensities, and to manually deﬁne regions of interest. ‘Periphery’ was deﬁned
as the outermost area with the strongest X-gal staining. Regions were drawn
manually and the pixel intensities for DAB (brown) and X-gal (blue) were
quantiﬁed on an 8-bit scale.
RNA in situ hybridization. The RNAScope 2.0 High Deﬁnition Kit (DAB)
(#310035) and the Multiplex Fluorescent Kit (#320850) were used35. The following
probes were all from Advanced Cell Diagnostics: Mus musculus leucine-rich repeat
containing G protein coupled receptor 5 (Lgr5), #312171; mRNA M. musculus
GLI-Kru¨ppel family member GLI1 (Gli1), mRNA, #311001; M. musculus Ihh
mRNA, #413096;M. musculus Grem1 mRNA, #314741;M. musculus Ptch1 mRNA,
#402811. Hybridization was performed according to the manufacturer’s protocol
with slight modiﬁcations (pre-treatment 2 was prolonged to 20min
and the developing time was extended to 15min). Expression was assessed
semi-quantitatively as suggested by the manufacturer from 0 (absent), 1 (sporadic
positive cells with single spots), 2 (frequent spots with occasional clusters of signal)
to 3 (abundant spots and clusters).
Real-time quantitative PCR. A 20–30mg sample of snap-frozen tissue was
disrupted using a VDI 12-homogenizator (VWR International) and mRNA was
extracted according to the manufacturer’s protocol using an RNeasy midi kit
(Qiagen, #75142). Real-time PCR was performed using the 7500 Fast Real-Time
PCR System (Applied Biosystems). Power Green PCR Master Mix (Applied
Biosystems; #4368708) comprised SYBR Green I Dye, AmpliTaq Gold DNA
Polymerase, dNTPs, buffer components and ROX as the passive reference dye. The
following primers were used: glyceraldehyde-3-phosphate dehydrogenase (Gapdh),
forward: 50-GGTGTGAACGGATTTGGCCGTATTG-30 , reverse: 50-CCGTTGAA
TTTGCCGTGAGTGGAGT-30; Rplp0/ARP, ribosomal protein, large, P0, forward:
50-TGCACTCTCGCTTTCTGGAGGGTGT-30 , reverse: 50-AATGCAGATGGATC
AGCCAGGAAGG-30; GLI family zinc ﬁnger 1 (Gli1), forward: 50-CGTTTAGCA
ATGCCAGTGACC-30 , reverse: 50-GAGCGAGCTGGGATCTGTGTAG-30 ; Ihh,
forward: 50-GGCTTCGACTGGGTGTATTA-30 , reverse: 50-CGGTCCAGGAAA
ATAAGCAC-30 ; Ptch1 forward: 50-TTGGGATCAAGCTGAGTGCTG-30 , reverse:
50-CGAGCATAGCCCTGTGGTTCT-30 ; Shh forward: 50-TGGAAGCAGGTTTC
GACTGG-30 , reverse: 50-GGAAGGTGAGGAAGTCGCTGT-30 . Gli2 forward:
50-TGAGGAGAGTGTGGAGGCCAGTAGCA-30 , reverse: 50-CCGGGGCTGGA
CTGACAAAGC-30 ; Hhip forward: 50-TAACGGCCCTTTGGTTGGTGGATTT-30 ,
reverse: 50-AGCAAAGCCCAGTGACCAAGCAATG-30 ; Lgr5 forward: 50-CCAAT
GGAATAAAGACGACGGCAACA-30 , reverse: 50-GGGCCTTCAGGTCTTCCT
CAAAGTCA-30 ; Axin2 forward: 50-CAGGAGGATGCTGAAGGCTCAAAGC-30 ,
reverse: 50-CTCAAAAACTGCTCCGCAGGCAAAT-30; Ihh forward: 50-GGCTTC
GACTGGGTGTATTA-30, reverse: 50-CGGTCCAGGAAAATAAGCAC-30 ;
Ptch2 forward: 50-CCCGTGGTAATCCTCGTGGCCTCTAT-30 , reverse: 50-TCCA
TCAGTCACAGGGGCAAAGGTC-30 ; Grem1 forward: 50-AGACCTGGAGACCC
AGAGTA-30 , reverse: 50-GTGTATGCGGTGCGATTCAT-30 ; Nog forward: 50-AA
GGATCTGAACGAGACGCT-30 , reverse: 50-GCGAAGTAGCCATAAAGCCC-30;
Chrd forward: 50-GATGCTGTTCCCACTGCAC-30 , reverse: GGCCCATCCTCT
TGGTCATA-30 ; and Bambi forward: 50-CGCCACTCCAGCTACTTCTT-30,
reverse: 50-TGAGCAGCATCACAGTAGCA-30 .
Gene expression microarrays. RNA was isolated from 1 cm of fresh-frozen whole
colonic tissue from Col1a2CreER;Ptch1ﬂ/ﬂ mice (n¼ 4) and controls (n¼ 4)
starting 1.5 cm proximal to the anus. RNA quality was assessed using the Agilent
2200 Tape Station system; RNA integrity numbers 48 were considered sufﬁcient.
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Affymetrix Mouse Gene ST 2.0 arrays were used. Robust multi-array average
median polish procedures were applied for normalization. For GSEA analyses58,
the GSEA Java plug-in v2.1.0 was used to probe non-log-transformed normalized
expression data with standard settings (with the exception that the permutation
type was set to ‘gene_set’ and gene setso15 genes were permitted). Gene lists were
derived either from publications as indicated, from the Molecular Signature
Database (www.broadinstitute.org/gsea/msigdb), or from gene ontology searches
via the AmiGO2 database v 2.1.4 (www.geneontology.org), curated to include
‘manual assertion’ and ‘experimental evidence’, and excluding ‘sequence similarity
evidence’ (see also Supplementary Tables 2–5 for the gene sets used).
TCGA query. Processed microarray data for colon adenocarcinoma
(AgilentG4502A_07_3) were analysed using gene expression data obtained from
TCGA2 accessed via the UCSC Cancer Browser59. In total, the data set obtained
included expression data for 155 primary tumours and 19 normal tissue samples.
All analyses were performed in R (version 3.1.1). Associations between GLI1
expression and the selected genes were evaluated using Spearman’s rank correlation
coefﬁcient. The correlations were derived using the rcorr function from the Hmisc
package. Differences in expression levels between tumours and normal tissue
samples were analysed using the Wilcoxon rank-sum test from the R stats package.
Pre-calculated ESTIMATE scores for the TCGA colon adenocarcinoma data
were retrieved from the ESTIMATE web repository (http://ibl.mdanderson.org/
estimate/)60.
Analysis of GEO data sets. Data for the GEO data sets GSE67186, GSE39395,
GSE17840 and GSE29316 were retrieved from the GEO website (http://
www.ncbi.nlm.nih.gov/geo). For RNA-sequencing data (GSE67186), DESeq61
was used to normalize the raw count data and to test for differential expression
comparing both the control (shRenilla) to each treatment group (shAPC and
shAPC/Kras) and the treatment groups to each other. Microarray data from
Affymetrix Human Genome U133 Plus 2.0 (GSE39395 and GSE29316) and
Affymetrix Mouse Genome 430 2.0 arrays (GSE17840) were robust multi-array
average normalized using the affy package62 and differential expression between
treatment groups was analysed using limma63. For GSE39395, gene expression in
stromal cells was compared with both epithelial cells and leukocytes, whereas in the
cases of GSE29316 and GSE17840, Hh-ligand treated cells were compared with
untreated or vehicle-treated controls. The expression pattern of a priori selected
genes was subsequently analysed and differential expression was called based on an
fdro 0.05.
Statistics. All data (except for microarray and sequencing data) were analysed
using GraphPad Prism v6.0e and are presented as the mean and s.e.m. unless
otherwise speciﬁed in the ﬁgure legends. Statistical tests are indicated in the ﬁgure
legends. All t-tests were two-sided. The type 1-error rate was set to 5%, except
for GSEA, for which results with an fdr o0.25 were considered signiﬁcant as
previously suggested58.
Study approval. All animal experiments were performed in accordance with local
ethical guidelines and with approval from the local ethics committee (the Swedish
Board of Agriculture and the Animal Ethics Committee of the Amsterdam Medical
Center, The Netherlands).
Data availability. The gene expression data that support the ﬁndings of this study
have been deposited at GEO (with the accession code GSE67172); expression data
referenced in this study are available in GEO (GSE67186 (ref. 21), GSE39395
(ref. 38), GSE17840 (ref. 14) and GSE29316 (ref. 33)). All other data that support
the ﬁndings of this study are available from the corresponding author (R.T.) upon
request.
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to ‘Haematoxylin, Casp-3’ during the production process. The correct version of Fig. 6 appears below as Fig. 1.
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